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Abstract This commentary is focusing on novel aspects
on the secreted CgA- and SgII-derived peptides, vasostatin-
I (bovine and human CgA1–76, VS-I), WE-14 (CgA316–329),
catestatin (bovine CgA344–366, human CgA352–372, Cts) and
the SgII-derived secretoneurin (SgII180–204) as significant
regulators of inflammatory reactions.
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The regulatory roles of granins in sorting and secretion still
dominate as topics at the international symposia on chro-
maffin cell biology (ISCCB), as indeed evident from the
15th ISCCB in Merida, Mexico, November 12–16, 2010. In
this article, only 2 out of 12 sessions were devoted to
effects of secreted granins such as Chromogranin A (CgA)
and Secretogranin II (SgII). Consequently, among the nine
contributions dealing with granins in the proceedings of
this meeting, there is only one review dealing with the
modulating effects of CgA and its N-terminal peptide va-
sostatin-I (VS-I) on growth and vascularization of neuro-
endocrine tumors (Corti 2010). In addition, there is one
original contribution concerning cardiovascular aspects of
the CgA peptide catestatin (Penna et al. 2010). Thus,
despite more than four decades since the first documented
co-secretion of the water-soluble, granule-specific protein
(later to be named CgA) and catecholamines by exocytosis
in vitro (Banks and Helle 1965) and in vivo (Blaschko et al.
1967), aspects of the granins in amine and peptide storage
and release have remained in focus at the expense of the
extracellular impact of the granin cargo as prohormones for
regulatory peptides. Hence, it seems timely to balance the
overall picture with a commentary focusing on novel
aspects on VS-I (bovine and human CgA1–76, VS-I) and
catestatin (bovine CgA344–366, human CgA352–372, Cts) and
the SgII-derived secretoneurin (SgII180–204) as significant
players in inflammatory processes (Helle 2010a, b).
The prohormone concept (Eiden 1987) implies that
rather than being biologically inert ‘‘garbage’’ from the
diffuse neuroendocrine system, the granins may serve as
precursors of smaller peptides that, once released into the
extracellular space, may serve some autocrine, paracrine,
and/or endocrine function. The experimental support for
this concept is escalating, notably for CgA and SgII. A
wide range of processes, such as innate immunity,
inflammatory and autoimmune reactions, cardiovascular
modulations and several homeostatic regulations are
affected (Metz-Boutigue et al. 1998; Fischer-Colbrie et al.
2005; Helle et al. 2007; Helle 2009, 2010a, b; Mahapatra
2008). Notably CgA and SgII appear to be involved in
mechanisms of disease, such as hypertension, heart failure,
and inflammatory syndromes.
The accumulated literature has brought forth novel
insight notably into the oppositely directed actions of the
most conspicuous peptides derived from the secreted CgA
and SgII, namely, VS-I, Cts and SN on elements involved
in combat of inflammatory insults.
VS-I and Cts by their concerted antimicrobial effects
may be relevant for the first-line host-defense against
invading microorganisms (Metz-Boutigue et al. 1998;
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Helle et al. 2007), while SN, seemingly devoid of antimi-
crobial potencies, may be regarded as an indirect contrib-
utor to innate immunity in view of its activation of
chemotaxis, transendothelial extravasation, and migration
of leukocytes (Fischer-Colbrie et al. 2005).
In this context, the oppositely directed effects of VS-I
and SN on permeability of the vascular endothelium (EC)
and on angiogenesis are particularly striking. Where SN
appears to induce EC permeability for transendothelial
transport of immunocompetent blood cells, VS-I seemingly
protects the integrity of the EC barrier against the disrup-
tive effects of pro-inflammatory agents. Wherever the
released SN might trigger transendothelial passage of
leukocytes including PMNs, a subsequent release of
CgA-derived VS-I and Cts from the activated PMNs might
serve to combat the microbial invasion. Moreover, an
initial SN-induced EC leakage might in due course be
reversed by the elevated plasma CgA and VS-I, protecting
EC against further barrier disruption in response to pro-
inflammatory cytokine.
A direct competition between VS-I and SN on regula-
tion of EC permeability at any given time seems unlikely.
Alternatively, one may anticipate a time-lag between the
release of SgII and SN from sensory nerves and the
increase in circulating CgA and VS-I in response to an
inflammatory injury. Hence, the oppositely directed effects
of the CgA peptide VS-I and the SgII-derived SN on EC
integrity open for a new insight and understanding of the
interplay between sensory nerves, PMNs, and the diffuse
neuroendocrine system in inflammatory situations.
Intriguingly, VS-I and SN also appear to exert opposite
effects on new formation of blood vessels. While VS-I
appears to inhibit VEGF-induced cell migration, prolifer-
ation, morphogenesis, and invasion of collagen gels
inherent in angiogenesis (Corti 2010), SN has, in contrast,
been shown to activate EC chemotaxis, proliferation,
angiogenesis, and vascularization while inhibiting EC
apoptosis (Fischer-Colbrie et al. 2005), suggesting a sig-
nificant role for SN also in tissue repair.
The accumulated evidence also provides convincing
support for VS-I and Cts as regulatory peptides for the
cardiovascular system, converging on alleviation of sig-
nificant dysfunctions as part of several inflammatory con-
ditions. A novel link between elevated circulating CgA and
cardiovascular dysfunctions has been discussed in relation
to potential beneficial effects of these two highly conserved
CgA-derived peptides (Helle 2009, 2010a, b; Mahapatra
2008; Mahata et al. 2010). Intriguingly, CgA via the
WE-14 domain has most recently been proposed as an
autoantigen in the non-obese diabetic mouse model of type
1 diabetes (Stadinski et al. 2010).
To conclude, although the physiological impact of the
secreted CgA- and SgII-derived peptides is yet to be fully
understood, the accumulated evidence lends substantial
support to the hypothesis that the co-stored and co-released
CgA and SgII serve as prohormones for regulatory peptides
with impact on a wide range of normal and pathophysio-
logical functions, notably those related to protecting the
organism against the debilitating effects of mechanical
injury and inflammations.
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